Trading
Data
Solutions
Insights
About
Comanche Biopharma is a drug development company that uses pre-clinical biopharmaceutical research with the goal of lowering risks associated with pregnancy. With a mission to create accessible therapies that treat the root cause of preeclampsia, Comanche Biopharma designed molecules that decrease excess protein production, or sFlt1, as the biggest target of the disease. Comanche Biopharma was founded by Mike Young and Thomas Scott Johnson in 2020 and is headquartered in Concord, MA.
Comanche Biopharma is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Comanche Biopharma pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Comanche Biopharma is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
